Effects of PPARg agonist pioglitazone on rat hepatic fibrosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

320

HTML

2134

Figures (1-4)

161

Tables (1-3)

172

Sum=2787

Apr 1, 2004 (publication date) through Jul 22, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Apr 1, 2004; 10(7): 1047-1051
Published online Apr 1, 2004. doi: 10.3748/wjg.v10.i7.1047

Table 3 Effects of pioglitazone on serum fibrotic markers in fibrotic rats (mean ± SD)

^aP < 0.05,

^bP < 0.01 vs model group;

^dP < 0.001 vs control group.

Citation: Yuan GJ, Zhang ML, Gong ZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 2004; 10(7): 1047-1051
URL: https://www.wjgnet.com/1007-9327/full/v10/i7/1047.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i7.1047